Ceryvyn Therapeutics Limited is an Australian clinical-stage biopharmaceutical company focused on developing biologic therapies for rare and serious diseases. Its current work centers on lymphangioleiomyomatosis (LAM), a progressive lung disorder that predominantly affects women, with a lead program designed to address the underlying biology of abnormal lymphatic growth. The company also has a broader history of researching vascular endothelial growth factor (VEGF) biology and applying that expertise to diseases with unmet medical need. Ceryvyn Therapeutics Limited operates in the biotechnology and healthcare sectors, where it contributes to the development of targeted treatments aimed at specific disease mechanisms rather than broad symptomatic care. The company is headquartered in Australia and serves research, clinical development, and therapeutic innovation markets through its drug-development activities.